Skip to main content
. Author manuscript; available in PMC: 2012 Mar 2.
Published in final edited form as: Cell Metab. 2011 Mar 2;13(3):320–330. doi: 10.1016/j.cmet.2011.02.001

Figure 5.

Figure 5

Cumulative chow intake following (A) hindbrain (4th icv) delivery of Ex-4 (0.025μg and 0.05μg in 1μl), (B) unilateral intraparenchymal mNTS delivery of Ex-4 (0.025μg and 0.05μg in 100nl), (C) unilateral intraparenchymal DMV delivery of Ex-4 (0.05μg in 100nl), (D) intraparenchymal AP delivery of Ex-4 (0.025μg and 0.05μg in 100nl), counterbalanced with aCSF. (E) Functional verification of AP injections measured by cumulative 4h chow intake following AP administration of the amylin (calcitonin) receptor agonist, salmon calcitonin (sCT) (0.4μg in 100nl) counterbalanced with aCSF. Data are mean ± SEM. * = P< 0.05 from aCSF.